TruSight Oncology 500 Training

Many next-generation sequencing applications use the Polymerase Chain Reaction, or PCR, for DNA amplification. This video presents best practices to minimize the potential for PCR contamination in your experiment.

Recorded Webinar (June 2020) |  TruSight Oncology 500 is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers with FFPE samples. The assay supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI). This webinar focuses on introducing TruSight Oncology 500/TruSight Oncology 500 High Throughput library preparation and is targeted at new users of the workflow. We will go over the following topics: How to successfully prepare and sequence TruSight Oncology 500 and TruSight Oncology 500 libraries, comparision of TruSight Oncology 500 and TruSight Oncology 500 High Throughput workflows, and how to assess key sequencing metrics.

Recorded Webinar (June 2020) |  TruSight Oncology 500 is a next-generation sequencing tumor profiling assay that analyzes 523 genes for cancer-related biomarkers and supports the identification of DNA and RNA variants implicated in various tumor types, including measuring key immunotherapy biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI). This provides an overview of TruSight Oncology 500 analysis and is targeted at new users of the TruSight Oncology 500 workflow. We will go over the following topics: overview of the TruSight Oncology analysis workflow, how to assess biomarker (TMB and MSI) results, and options for data analysis and variant interpretation.